Nymox Pharmaceutical Corp ROCE
Was ist das ROCE von Nymox Pharmaceutical Corp?
ROCE von Nymox Pharmaceutical Corp ist -3,533.74%
Was ist die Definition von ROCE?
Die Kapitalerträge (ROCE) entsprechen einer Finanzkennzahl, die die Rentabilität eines Unternehmens und die Effizienz, mit der sein Kapital verwendet wird, misst.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Nymox Pharmaceutical Corp
Was macht Nymox Pharmaceutical Corp?
nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.
Unternehmen mit roce ähnlich Nymox Pharmaceutical Corp
- Annovis Bio hat ROCE von -4,349.07%
- Forum Merger III hat ROCE von -4,294.27%
- On Track Innovations hat ROCE von -3,978.00%
- On Track Innovations hat ROCE von -3,978.00%
- Alpha MOS SA hat ROCE von -3,650.00%
- Therapix Biosciences hat ROCE von -3,621.30%
- Nymox Pharmaceutical Corp hat ROCE von -3,533.74%
- Novabay Pharmaceuticals Inc hat ROCE von -3,385.40%
- Akorn hat ROCE von -3,206.05%
- Class 1 Nickel and Technologies hat ROCE von -3,055.32%
- Major Precious Metals hat ROCE von -3,049.61%
- Goldhills hat ROCE von -2,716.05%
- Datasea hat ROCE von -2,450.25%